LifeMD Q2 Revenue $47.3M; Revises FY26 Guidance; Expects H2 Positive EBITDA

LifeMD, Inc. reported Q2 2026 revenue of $47.3 million, meeting its guidance range, and an adjusted EBITDA loss of $3.5 million, a 21% sequential improvement. The company saw gross margin expand to 89% and total active subscribers grow 20% year-over-year to 356,000, including 108,000 Weight Management Program subscribers. LifeMD also launched a co-marketing collaboration for XYOSTED® and expects to return to positive adjusted EBITDA in the second half of 2026. However, the company revised its full-year 2026 revenue guidance downwards to $205.5 million to $212.5 million and adjusted EBITDA guidance to negative $6.0 million to breakeven.